FindTrial
Sign In

Study to understand clinical utility of Ticagrelor in cardiac disorder.

A retrospective, Cross-sectional study on Ticagrelor usage pattern and tolerability in acute coronary syndrome (CROSS-TIC) - CROSS-TIC

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/08/093318
Enrollment
15000
Registered
2025-08-20
Start date
Unknown
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I200- Unstable angina Health Condition 2: I21- Acute myocardial infarction

Interventions

Intervention1: Nil: Nil

Sponsors

Torrent Pharmaceuticals Ltd.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male or female patients 18 years and above 2. Patients with history of MI or diagnosed with ACS and treated with ticagrelor

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
1. Proportion of patients with ACS on DAPT of ticagrelor and aspirinTimepoint: Baseline—

Secondary

MeasureTime frame
1. Proportion of patients with ACS on DAPT of ticagrelor & aspirin stratified by treatment duration 2. TolerabilityTimepoint: Baseline—

Countries

India

Contacts

Public ContactDr Mukesh Gabhane

Torrent Pharmaceuticals Ltd.

mukeshgabhane@torrentpharma.com7069000639

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Sep 19, 2026